Skip to main content

Table 1 Summary of outcomes from SITS-MOST, meta-analysis of previous rt-PA trials and placebo arm

From: Acute stroke: we have the treatments and we have the evidence – we need to use them

 

Mortality (at 3/12)

Independence (at 3/12)

Symptomatic ICH (per SITS-MOST)a

Symptomatic ICH (per previous trials)b

Trials

17.3%

49%

N/A

8.6%

SITS-MOST

11.3%

54.8%

1.7%

7.3%

Placebo

18.4%

30.2%

N/A

1.9%

  1. aBleed large enough to cause symptoms and accompanying neurological deterioration. bAny bleed with any alteration in neurological status, regardless of severity. rt-PA, recombinant tissue-plasminogen activator; SITS-MOST, Safe Implementation of Thrombolysis in Stroke Monitoring Study.
Back to article page

Critical Care

ISSN: 1364-8535